ION BIOTECHNOLOGY (USA), INC.
Ion Biotechnology has a family of therapeutic technologies using ions including ionic metals. These ionic technologies are theorized to target cells which do not follow the full Krebs metabolic cycle. This may include cancer cells, bacteria, and other pathogens.
ION BIOTECHNOLOGY (USA), INC.
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2017-01-10
Website Url:
http://www.ionbiotech.com
Total Employee:
1+
Status:
Active
Contact:
(832)628-2212
Technology used in webpage:
Amazon Google Apps For Business GoDaddy DNS AWS Global Accelerator WordPress Hosting
Similar Organizations
Sunol Molecular
A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.
Xori Corporation
XORI Corporation develops technology for discovery and development of monoclonal antibodies which are used to treat cancers, immune
Current Employees Featured
Dennis Stone CEO @ Ion Biotechnology (USA), Inc.
CEO
2017-01-10
Official Site Inspections
http://www.ionbiotech.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ion Biotechnology (USA), Inc."
IO Biotech, Inc. - Governance - Board of Directors
Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization, and Valo Therapeutics Ltd., a biotechnology company.See details»
IO Biotech, Inc. - Governance - Executive Management
Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for …See details»
IO Biotech, Inc. - Invest in combination cancer therapy
Mar 4, 2025 IO Biotech is a clinical-stage biopharmaceutical company pioneering the first dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of …See details»
IO Biotech - Crunchbase Company Profile & Funding
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.See details»
IO Biotech - LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based ...See details»
IO Biotech, Inc. (IOBT) Company Profile & Facts - Yahoo Finance
See the company profile for IO Biotech, Inc. (IOBT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
IO Biotech - Craft
Oct 2, 2024 IO Biotech has 1 employees across 4 locations. See insights on IO Biotech including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
IO Biotech Strengthens Executive Management and US Presence …
Jul 18, 2023 Over the past 6 years, IO Biotech has grown from a 10-person organization to a publicly traded, international company with a pipeline of clinical programs and more than 60 …See details»
IO Biotech Named Among Fast Company’s World’s Most
Mar 18, 2025 Contact: Investors Maryann Cimino, Director of Investor Relations IO Biotech, Inc. 617-710-7305 mci@iobiotech.com Media Julie Funesti Edelman 917-498-1967 …See details»
IO Biotech, Inc. - IO Biotech Strengthens Executive Management …
Jul 18, 2023 Over the past 6 years, IO Biotech has grown from a 10-person organization to a publicly traded, international company with a pipeline of clinical programs and more than 60 …See details»
IO Biotech Announces Acceptance of Abstract to be Presented
Mar 6, 2024 Release Summary IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingSee details»
Posters & Publications - IO Biotech
Nov 8, 2022 SITC 2024 Phase 2 trial of the IO1O2-IO103 cancer vaccine plus pembrolizumab Results from the first-line cohort of PD-L1 high metastatic non-small cell lung cancer Dr. …See details»
IO Biotech - HBM Partners
Description - IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of first-in-class immune modulating anti …See details»
Immune modulatory cancer vaccines against IDO1 and PD-L1 …
Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models Marion Chapellier1, Evelina …See details»
IO Biotech, Inc. - IO Biotech Announces an Invited Oral …
Nov 9, 2022 About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient …See details»
IO Biotech Announces New Head and Neck Cohort Data Accepted …
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer …See details»
News - IO Biotech
– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE …See details»
IO Biotech Presents New Data at AACR 2024 Further Supporting …
Apr 9, 2024 Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) - IO Biotech (Nasdaq: …See details»
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to …
Mar 24, 2025 Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder.See details»
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
Dec 31, 2022 Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or …See details»